US2002064522A1PendingUtilityA1

Interleukin-12 inducer and medical composition

53
Priority: Nov 11, 1996Filed: Dec 3, 2001Published: May 30, 2002
Est. expiryNov 11, 2016(expired)· nominal 20-yr term from priority
Inventors:Akikuni Yagita
A61K 36/06A61P 35/00A61K 35/744A61K 31/717A61P 43/00A61K 36/074A61K 36/07
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition comprising activated hemicellulose (AHCC), a method for inducing IL-12 in a living body having tumor cells by administering the composition, and a method for treating cancer by administering the composition are provided.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A pharmaceutical composition comprising activated hemicellulose as an active ingredient in an amount effective to induce interleukin-12 and a pharmaceutically acceptable carrier.  
     
     
         2 . The pharmaceutical composition as claimed in  claim 1 , which further contains components of fungal mycelium.  
     
     
         3 . The pharmaceutical composition as claimed in  claim 2 , which further contains bacterial components of hemolytic streptococci.  
     
     
         4 . A method for inducing interleukin-12 in vivo, comprising administering a pharmaceutical composition containing activated hemicellulose as an active ingredient and a pharmaceutically acceptable carrier.  
     
     
         5 . The method for inducing interleukin-12 in vivo as claimed in  claim 4 , wherein said pharmaceutical composition further contains components of fungal mycelium.  
     
     
         6 . The method for inducing interleukin-12 in vivo as claimed in  claim 5 , wherein said pharmaceutical composition further contains bacterial components of hemolytic streptococci.  
     
     
         7 . A method for treating cancer, comprising administering a pharmaceutical composition containing activated hemicellulose (AHCC) as an active ingredient and a pharmaceutically acceptable carrier by a single or simultaneous use in an amount which can induce interleukin-12 in vivo.  
     
     
         8 . The method for treating cancer as claimed in  claim 7 , wherein said pharmaceutical composition further contains components of fungal mycelium.  
     
     
         9 . The method for treating cancer as claimed in  claim 8 , wherein said pharmaceutical composition further contains bacterial components of hemolytic streptococci.  
     
     
         10 . The pharmaceutical composition according to  claim 1 , further comprising shark cartilage.  
     
     
         11 . The method according to  claim 4 , further comprising administering shark cartilage.  
     
     
         12 . The pharmaceutical composition as claimed in  claim 1 , wherein the activated hemicellulose is selected from the group consisting of a β-D-glucan and an α-D-glucan.  
     
     
         13 . The pharmaceutical composition as claimed in  claim 1 , wherein the activated hemicellulose is a mixture of a β-D-glucan and an α-D-glucan.  
     
     
         14 . The method for inducing interleukin-12 in vivo as claimed in  claim 4 , wherein the activated hemicellulose is selected from the group consisting of a β-D-glucan and an α-D-glucan.  
     
     
         15 . The method for inducing interleukin-12 in vivo as claimed in  claim 4 , wherein the activated hemicellulose is a mixture of a β-D-glucan and an α-D-glucan.  
     
     
         16 . The method for treating cancer as claimed in  claim 7 , wherein the activated hemicellulose is selected from the group consisting of a β-D-glucan and an α-D-glucan.  
     
     
         17 . The method for treating cancer as claimed in  claim 7 , wherein the activated hemicellulose is a mixture of a β-D-glucan and an α-D-glucan.

Join the waitlist — get patent alerts

Track US2002064522A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.